This Article Full Text Full Text (PDF) All Versions of this Article: 147/1/70    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nardelli, B. Articles by Moore, P. A. Search for Related Content PubMed PubMed Citation Articles by Nardelli, B. Articles by Moore, P. A.

Osteostat/Tumor Necrosis Factor Superfamily 18 Inhibits Osteoclastogenesis and Is Selectively Expressed by Vascular Endothelial Cells

Human Genome Sciences, Inc., Rockville, Maryland 20850

Address all correspondence and requests for reprints to: Paul Moore, Ph.D., Celera, 45 West Gude Drive, Rockville, Maryland 20850. E-mail: paul.moore{at}celera.com.

Vascular endothelial cells (EC) participate in the process of bone formation through the production of factors regulating osteoclast differentiation and function. In this study, we report the selective expression in primary human microvascular EC of Osteostat/TNF superfamily 18, a ligand of the TNF superfamily. Osteostat protein is detectable in human microvascular EC and is highly up-regulated by IFN- and IFN-ß. Moreover, an anti-Osteostat antibody strongly binds to the vascular endothelium in human tissues, demonstrating that the protein is present in the EC layers surrounding blood vessels. Functional in vitro assays were used to define Osteostat involvement in osteoclastogenesis. Both recombinant and membrane-bound Osteostat inhibit differentiation of osteoclasts from monocytic precursor cells. Osteostat suppresses the early stage of osteoclastogenesis via inhibition of macrophage colony-stimulating factor-induced receptor activator of NF-B (RANK) expression in the osteoclast precursor cells. This effect appears to be specific for the differentiation pathway of the osteoclast lineage, because Osteostat does not inhibit lipopolysaccharide-induced RANK expression in monocytes and dendritic cells, or activation-induced RANK expression in T cells. These findings demonstrate that Osteostat is a novel regulator of osteoclast generation and substantiate the major role played by the endothelium in bone physiology.

This article has been cited by other articles:

				G. NOCENTINI, S. CUZZOCREA, R. BIANCHINI, E. MAZZON, and C. RICCARDI Modulation of Acute and Chronic Inflammation of the Lung by GITR and its Ligand Ann. N.Y. Acad. Sci., June 1, 2007; 1107(1): 380 - 391. [Abstract] [Full Text] [PDF]